Cencora, Inc. (COR) Financial Statements
Historical financial data — 21 statements covering FY2021–FY2025
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, an...
Cencora, Inc.'s revenue increased 9.3% year over year, from $293.96B to $321.33B.
Net income increased 3.0% over the same period, from $1.51B to $1.55B.
Over the 4-year period from FY2021 to FY2025, revenue grew by 50% in total.
Total debt increased by 74.6% to $7.66B.
The debt-to-equity ratio stands at 5.08, indicating a high leverage profile.
Operating cash flow grew 11.2% to $3.88B.
Cencora, Inc. maintains a moderate net profit margin of 0.5%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q4 FY2024 | $79.05B+6.5% | $3.4M | $2.49B | $126.6M | $1.00B | $67.10B | $4.39B | $645.9M |
| Q1 FY2025 | $81.49B+3.1% | $488.6M | $2.56B | $706.3M | $-2.72B | $69.05B | $8.15B | $226.6M |
| Q2 FY2025 | $75.45B-7.4% | $717.9M | $3.06B | $1.04B | $3.35B | $71.19B | $7.86B | $1.01B |
| Q3 FY2025 | $80.66B+6.9% | $687.4M | $2.91B | $867.7M | $109.2M | $73.96B | $8.24B | $1.98B |
| Q4 FY2025 | $83.73B+3.8% | $-339.7M | $2.95B | $18.5M | $3.13B | $76.59B | $7.66B | $1.51B |
| Q1 FY2026 | $85.93B+2.6% | $559.6M | $3.07B | $760.4M | $-2.31B | $78.36B | $7.92B | $1.91B |
| Q2 FY2026 | $78.36B-8.8% | $1.64B | $3.59B | $1.14B | $1.34B | $81.65B | $15.09B | $3.58B |
| Q3 FY2026 | $84.75B+8.2% | $763.5M | $3.61B | $1.12B | $2.65B | $83.81B | $14.46B | $3.24B |
Balance Sheet Summary (Q3 FY2026)
Cencora, Inc. (COR) Financial Statements & Revenue History
Cencora, Inc. (COR) is a US-listed stock operating in the Healthcare sector, specifically the Wholesale-Drugs, Proprietaries & Druggists' Sundries industry trading at $340.92 with a market capitalization of $65. This page provides 21 historical financial statements for Cencora, Inc., including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Cencora, Inc. reported revenue of $321.3 billion, representing 9.3% year-over-year growth. The net profit margin of 0.5% suggests thin margins. The debt-to-equity ratio of 5.08 signals high leverage.
COR Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Cencora, Inc.'s revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether COR is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track COR's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Cencora, Inc. converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of COR's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use COR Financial Data
Investors use Cencora, Inc.'s financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare COR's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how COR's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View COR's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Cencora, Inc.'s SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.COR trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.